EC Number   |
Application |
Reference |
|---|
    1.13.11.33 | drug development |
15-LO-1 is an attractive pharmacological target for treatment of inflammatory respiratory diseases like asthma, rhinitis and chronic obstructive pulmonary disease |
706579 |
| 1.13.11.33 | drug development |
systemic delivery of cholesterol-tagged siRNAs targeting 12/15-LO has renoprotective effects under diabetic conditions and therefore can be a novel therapeutic approach for diabetic nephropathy |
-, 701636 |
| 1.13.11.33 | drug development |
trials of 15LO1 pathway inhibitors in asthma may be a promising treatment strategy |
701642 |
| 1.13.11.33 | medicine |
15 lipoxygenase 1 is abundant in asthmatic human airway epithelial cells and binds phosphatidylethanolamine-binding protein 1 (PEBP1), leading to generation of hydroperoxy-phospholipids, which drive ferroptotic cell death. 15LO1, PEBP1, and glutathione peroxidase 4 GPX4 activity drives abnormal asthmatic redox biology, to enhance type 2 inflammatory responses. In vitro, type 2 inflammatory cytokine IL-13 induces 15LO1 generation of hydroperoxy-phospholipids, which lowers intracellular GSH and increased extracellular GSSG levels. Lowering GSH further by inhibiting cystine transporter SLC7A11 enhances type 2 inflammatory protein expression and ferroptosis. Ex vivo, redox imbalances correspond to 15LO1 and SLC7A11 expression, type 2 inflammatory biomarkers, and worsen clinical outcomes |
765145 |
| 1.13.11.33 | medicine |
15-LOX-1 and its metabolites (13-S-hydroxyoctadecadienoic acid and 15-S-hydroxyeicosatetraenoic acid) have anti-carcinogenic effects in colorectal cancer. 15-LOX-1 is possibly of prognostic value in stage IV colon cancer survival |
706877 |
| 1.13.11.33 | medicine |
15-LOX-2 is a negative regulator of tumor growth via downregulating angiogenesis |
704067 |
| 1.13.11.33 | medicine |
15-LOX-2 may be a potential target in radiation-targeted therapy of head-and-neck cancer |
703002 |
| 1.13.11.33 | medicine |
application of 14(S)-hydroxy docosahexaenoic acid suppresses IL-33-mediated eosinophilic inflammation in 12/15-LOX-deficient mice. 14(S)-hydroxy docosahexaenoic acid and 10(S),17(S)-dihydroxy docosahexaenoic acid markedly attenuate ILC2 proliferation and cytokine production at micromolar concentration in vitro. Maresin 1 (MaR1) and resolvin D1 (RvD1), 12/15-LOX-derived specialized proresolving mediators (SPMs), inhibited cytokine production of ILC2s at nanomolar concentration |
764729 |
| 1.13.11.33 | medicine |
gene ALOX15 has potential as a therapeutic target for eradicating leukemia stem cells in chronic myeloid leukemia |
742977 |
| 1.13.11.33 | medicine |
has anti-carcinogenic effects in colorectal cancer |
706877 |
